Drug intelligence / Profile preview

YS-HBV-001

Development stage: Unknown
Lead developer: LakeShore Biopharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

YS-HBV-001 is a therapeutic and prophylactic vaccine candidate for Hepatitis B virus (HBV) infection, developed by LakeShore Biopharma (formerly Yisheng Biopharma). The vaccine utilizes the company's proprietary PIKA immunomodulating technology, which acts as a Toll-like receptor 3 (TLR3) agonist to enhance the immune response. It is designed to induce both humoral and cellular immunity against HBV. Clinical development has progressed to Phase 1 trials in Singapore, targeting both the prevention and treatment of chronic hepatitis B.

Other names: PIKA HBV vaccine

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on YS-HBV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YS-HBV-001.

Explore the full profile